沙丁胺醇联合布地奈德对咳嗽变异性哮喘的治疗

目的观察沙丁胺醇联合布地奈德对咳嗽变异性哮喘疗效。方法纳入CVA患儿64例为观察对象,随机分为观察组和对照组各32例。两组均给予布地奈德气雾剂吸入,布地奈德2～7岁：200μg,2次/d;7岁以上：400μg,2次/d。咳嗽停止后续用至疗程满3个月改为200μg1次/d,维持3个月。同时,观察组给予沙丁胺醇气雾剂,每次1喷,3次/d。咳嗽消失后停药;对照组口服氯雷他定,体重＆gt;30kg：10mg,1次/d。体重≤30kg：5mg,1次/d。两组计入观察的疗程均为前3个月,峰流速仪测量最高呼气流速。结果①两组患者咳嗽消失率均为100%,观察组咳嗽消失时间为平均（9.75±4.90）d,对照组（13.83±6.19）d,两组比较有显著性差异（P〈0.05）;②治疗后两组PEF值均有显著增加（P〈0.05）,观察组晨、晚间PEF与观察组比较差异无显著性（P〈0.05）。结论吸入型速效β2受体激动剂可快速有效缓解CVA患者咳嗽症状。

Treatment with Budesonide and salbutamol on cough variant asthma

Objective To observe the combined budesonide salbutamol on cough variant asthma. Methods 64 cases of children into the CVA for the observation of objects,were randomly divided into observation group and 32 cases of the control group. Both groups were given budesonide inhalation aerosol, budesonide 2 -7 years old：200 μg,2 times; 7 years of age：400 μg,2 times. Coughing to stop the follow-up to treatment by age 3 months changed to 200 μg per day 1, maintenance for 3 months. At the same time, the observation group to give salbutamol aerosol, 1 spray per day 3 times. After the withdrawal cough; control group oral loratadine, weight 〉30 kg：10mg,day 1. Weight ≤ 30 kg：5 mg,Day 1. Observation of the treatment groups were included in the first 3 months, the highest peak expiratory flow rate measurement. Results （1） The disappearance of the two groups of patients with cough 100% ,the observation group the average time for the disappearance of cough （9. 75 ± 4. 90） days, the control group（ 13.83± 6. 19） days, two groups were significantly different（ P 〈 0. 05 ） ; （2）PEF values of the two groups after treatment were significantly increased （ P 〈 0.05 ）, the observation group morning, evening PEF compared with the observation group there was no significant difference （ P 〈 0. 05 ）. Conclusion Inhaled β2 agonists can be available quickly and efficiently to alleviate cough in patients with CVA.